Roman Hájek

37.5k total citations · 3 hit papers
567 papers, 10.9k citations indexed

About

Roman Hájek is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Roman Hájek has authored 567 papers receiving a total of 10.9k indexed citations (citations by other indexed papers that have themselves been cited), including 381 papers in Hematology, 275 papers in Molecular Biology and 226 papers in Oncology. Recurrent topics in Roman Hájek's work include Multiple Myeloma Research and Treatments (362 papers), Protein Degradation and Inhibitors (119 papers) and Cancer Treatment and Pharmacology (95 papers). Roman Hájek is often cited by papers focused on Multiple Myeloma Research and Treatments (362 papers), Protein Degradation and Inhibitors (119 papers) and Cancer Treatment and Pharmacology (95 papers). Roman Hájek collaborates with scholars based in Czechia, United States and Spain. Roman Hájek's co-authors include Meletios Α. Dimopoulos, Sabina Ševčı́ková, Tomáš Jelı́nek, Jesús F. San Miguel, Lenka Sedlaříková, Lenka Kubiczková, Pieter Sonneveld, Philippe Moreau, Heinz Ludwig and Hartmut Goldschmidt and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Roman Hájek

513 papers receiving 10.7k citations

Hit Papers

Multiple myeloma: ESMO Clinical Practice... 2007 2026 2013 2019 2017 2007 2021 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2017 518 citations Philippe Moreau, Pieter Sonneveld et al. profile →
  2. Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression
    2007 505 citations Pieter Sonneveld, Roman Hájek et al. Journal of Clinical Oncology profile →
  3. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
    2021 460 citations Meletios Α. Dimopoulos, Philippe Moreau et al. profile →

Peers

Roman Hájek
Seema Singhal United States
James R. Berenson United States
Michèle Cavo Italy
Efstathios Kastritis Greece
Hartmut Goldschmidt Germany
Jane L. Liesveld United States
Mario Boccadoro Italy
Roland B. Walter United States
Rainer Haas Germany
Mitsune Tanimoto Japan
Seema Singhal United States
Roman Hájek
Citations per year, relative to Roman Hájek Roman Hájek (= 1×) peers Seema Singhal

Countries citing papers authored by Roman Hájek

Since Specialization
Citations

This map shows the geographic impact of Roman Hájek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roman Hájek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roman Hájek more than expected).

Fields of papers citing papers by Roman Hájek

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roman Hájek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roman Hájek. The network helps show where Roman Hájek may publish in the future.

Co-authorship network of co-authors of Roman Hájek

This figure shows the co-authorship network connecting the top 25 collaborators of Roman Hájek. A scholar is included among the top collaborators of Roman Hájek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roman Hájek. Roman Hájek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Rückert, Michael, Mamta Garg, Ceri Bygrave, et al.. (2024). Evolution of Treatment Patterns and Survival Outcomes in European Patients with Multiple Myeloma from 2012-2023 through the Honeur Federated Data Network. Blood. 144(Supplement 1). 2388–2388.
3.
Chyra, Zuzana, et al.. (2024). Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies. Blood Cancer Journal. 14(1). 213–213. 15 indexed citations
4.
5.
6.
Thomsen, Hauke, Subhayan Chattopadhyay, Niels Weinhold, et al.. (2024). Haplotype analysis identifies functional elements in monoclonal gammopathy of unknown significance. Blood Cancer Journal. 14(1). 140–140. 1 indexed citations
7.
Chyra, Zuzana, Sigitas Verselis, Ivane Abiatari, et al.. (2023). Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeutics. Blood Cancer Journal. 13(1). 23–23. 3 indexed citations
8.
Sonneveld, Pieter, Paul G. Richardson, Heinz Ludwig, et al.. (2023). Benefit Versus Risk Assessment of Melflufen and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Analyses From Longer Follow-up of the OCEAN and HORIZON Studies. Clinical Lymphoma Myeloma & Leukemia. 23(9). 687–696. 5 indexed citations
9.
Štork, Martin, Sabina Ševčı́ková, Tomáš Jelı́nek, et al.. (2022). Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas. Biomedicines. 10(10). 2535–2535. 2 indexed citations
10.
Maisnar, Vladimír, Luděk Pour, Ivan Špıčka, et al.. (2022). Patient Characteristics, Treatment Patterns, and Outcomes in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Patients, a Retrospective Observational Study Using Czech Registry Data. Clinical Lymphoma Myeloma & Leukemia. 23(2). 145–153. 4 indexed citations
11.
Murray, David, Noemí Puig, Sigurður Y. Kristinsson, et al.. (2021). Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report. Blood Cancer Journal. 11(2). 24–24. 92 indexed citations
12.
Martin, Thomas G., Joseph Mıkhael, Roman Hájek, et al.. (2020). Depth of Response and Response Kinetics of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Interim Analysis. Blood. 136(Supplement 1). 7–8. 12 indexed citations
13.
Dimopoulos, Meletios Α., Ivan Špıčka, Hang Quach, et al.. (2020). Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial. Journal of Clinical Oncology. 38(34). 4030–4041. 53 indexed citations
14.
Konečný, Jan, et al.. (2018). Penetrating Injuries of the Heart and Great Vessels - Fifteen Years of Experience of the Cardiac Surgery Service as a Part of the Major Trauma Centre. Acta chirurgiae orthopaedicae et traumatologiae Cechoslovaca. 85(2). 144–148. 3 indexed citations
15.
Piskáček, Martin, Anna Vašků, Roman Hájek, & Andrea Knight. (2015). Shared structural features of the 9aaTAD family in complex with CBP. Molecular BioSystems. 11(3). 844–851. 17 indexed citations
16.
Hájek, Roman, et al.. (2015). Threats to Mutual Trust: Czech Local Politicians and Local Journalists in the Era of Professional Political Communication. SHILAP Revista de lepidopterología. 2 indexed citations
17.
Kryukov, Fedor, et al.. (2013). High-Risk Multiple Myeloma: Different Definitions, Different Outcomes?. Clinical Lymphoma Myeloma & Leukemia. 14(1). 24–30. 10 indexed citations
18.
Ludwig, Heinz, Luísa Viterbo, Richard Greil, et al.. (2012). Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma. Journal of Clinical Oncology. 31(2). 247–255. 58 indexed citations
19.
Ludwig, Heinz, Roman Hájek, Elena Tóthová, et al.. (2008). Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood. 113(15). 3435–3442. 148 indexed citations
20.
Pierce, John P., Marcia L. Stefanick, Shirley W. Flatt, et al.. (2007). Greater Survival After Breast Cancer in Physically Active Women With High Vegetable-Fruit Intake Regardless of Obesity. Journal of Clinical Oncology. 25(17). 2345–2351. 309 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Seema Singhal Breakdown of academic impact, for papers by James R. Berenson Breakdown of academic impact, for papers by Michèle Cavo Breakdown of academic impact, for papers by Efstathios Kastritis Breakdown of academic impact, for papers by Hartmut Goldschmidt Breakdown of academic impact, for papers by Jane L. Liesveld Breakdown of academic impact, for papers by Mario Boccadoro Breakdown of academic impact, for papers by Roland B. Walter Breakdown of academic impact, for papers by Rainer Haas Breakdown of academic impact, for papers by Mitsune Tanimoto
Rankless by CCL
2026